Fig. 1: IGFBP-2 Expression Levels in Glioblastoma Cells and Tissue Samples.
From: SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN
A–C Analyzing the expression of IGFBP-2 using single-cell sequencing data from the GSE138794 database. D CGGA database was used to analyse the expression levels of IGFBP-2 in different grades of gliomas. E CGGA database analysis of overall survival in patients with different expression levels of IGFBP-2. High (n = 202) and low (n = 202) levels of IGFBP-2, P < 0.05. F IHC was conducted to assess the expression levels of IGFBP-2 in human non-tumor brain tissue, low-grade (WHO I and II) glioma tissue, and high-grade (WHO III and IV) glioma tissue samples. All images were captured at 40× magnification. G Quantitative analysis was conducted on the immunohistochemical staining of low-grade and high-grade gliomas. H Plasma IGFBP-2 expression levels were measured by ELISA in a cohort of 58 subjects, including 29 healthy controls and 29 GBM patients. Statistical analysis: data were quantified as mean ± SD, n ≥ 3, two tailed student’s t test, P < 0.05, *; P < 0.0001, ****.
